[Results of the ECHODIAH clinical trial on hip arthrosis].
OBJECTIVE
The principal objective of ECHODIAH study conducted in patients with hip osteoarthritis was to evaluate the chondroprotective effect of potential of diacerein compared with placebo. The study was conducted over a 3-year period using progression of joint space narrowing as the assessment criterion.


RESULTS
For aggravation, expressed as joint space narrowing of at least 0.5 mm, there were significantly fewer patients in the diacerein group than in the placebo group; aggravation came significantly later in the diacerhein group. In the population of patients who completed at least 3 months treatment, the sparing effect on joint space narrowing was 32% in the diacerhein group compared with the placebo group. In addition, the mean progression of joint space narrowing was significantly less in patients treated with diacerein; the mean progression decreased from 0.18 mm/year at the end of the first year to 0.13 mm/year at the end of the third year.
Vignon
E
E
Service rhumatologie, Centre Hospitalier, Lyon Sud, 69495 Pierre Bénite.
D000880:Anthraquinones / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D015207:Osteoarthritis, Hip / Q000188:drug therapy*
D000880:Anthraquinones; D000894:Anti-Inflammatory Agents, Non-Steroidal; C025292:diacerein